Effects of HMOs on the Faecal Microbiota and on Host Metabolism in Obese Children

Inclusion criteria

• Informed, written consent by the child's representative(s) and informed verbal assent by the child
• Age ≥5 and <11 years at visit 0
• BMI SDS of ≥ 2.3
• Enrolment in the childhood obesity treatment program at the Children's Obesity Clinic
• Ability and willingness to understand and comply with the study procedures
• The child's representative(s) need(s) to read, speak and understand Danish

Exclusion criteria

• Participation in another clinical intervention study one month prior to the screening visit and throughout the study.
• Any gastrointestinal disease(s) that may cause symptoms or may interfere with the trial outcome, as judged by the investigator.
• Other severe disease(s) such as malignancy, kidney disease or neurological disease, as judged by the investigator.
• Psychiatric disease, as judged by the investigator.
• Use of probiotic supplements (yoghurt allowed) 3 months prior to screening and throughout the study.
• Consumption of antibiotic drugs 3 months prior to screening and throughout the study.
• Consumption on a regular basis of medication that might interfere with symptom evaluation (as judged by the investigator) 2 weeks prior to screening and throughout the study.
• Lack of suitability for participation in the study for any reason as judged by the investigator.